Key result
Pharmacological PPARα activation with pemafibrate, metformin, or GLP-1 RAs shows potential for managing diabetic cardiomyopathy.
Why the study?
Specific drugs for diabetic cardiomyopathy are lacking, partly due to incomplete understanding of how heart failure initiates and develops without an ischemic cause.
Design
Review
Authors
Loading...
May support PPARα-targeted agents in diabetic cardiomyopathy; leaves open confirmation in prospective trials before practice change.
This review provides a contemporary view of PPARα's role in the pathophysiology of diabetic cardiomyopathy and discusses the potential of PPARα-related drugs in its management.
Wang et al. (2021) conducted a review in Diabetic cardiomyopathy. PPARα modulators was evaluated. Pharmacological targeting of PPARα activation with agents such as pemafibrate, metformin, and GLP-1 receptor agonists offers a potential therapeutic strategy for managing diabetic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: